Article
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2022
Shi Yuankai, Li Baolan, Wu Lin, Pan Yueyin, Pan Zhijie, Liu Yunpeng, Fan Yun, Ji Yinghua, Fang Jian, Shi Qin, Shi Jianhua, Gao Hongjun, Hu Yanping, Wang Xiang, He Zhiyong, Ma Rui, Zhang Yu, Jiang Da, Bai Yuansong, Zhang Yi, Huang Linian, Zhou Tong, Liu Hailong, Wang Daqing, Wen Qinglian, Chen Gongyan, Zang Aimin, Wang Xiuwen, Zhang Xinri, Hu Jianbing, Yang Runxiang, Zhang Guojun, Gu Kangsheng, Wang Lin, Wang Qiming, Wei Zonghui, Li Zeng, Lu Hongda, Zhang Helong, Chen Hongyu, Song Tingting
Abstract excerpt
INTRODUCTION: Limertinib (ASK120067) is a newly developed third-generation EGFR tyrosine kinase inhibitor targeting both sensitizing EGFR and EGFR Thr790Met (T790M) mutations. This study aimed to evaluate the efficacy and safety of limertinib in patients with locally advanced or metastatic EGFR T790M-mutated NSCLC. METHODS: This is a single-arm, open-label, phase 2b study conducted at 62 hospitals across the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.